Psaio Therapeutics
Our mission is to meet the unmet need in prostate cancer by developing novel immunotherapies
Our Technology
Psaio Therapeutics is solely focused on developing immunotherapies for prostate cancer
Capital Raise
In mid-2024 we are raising AU$2m in equity capital to fund our 2 lead candidate antibodies through to the completion of in vivo testing for efficacy and toxicity. We invite expressions of interest from potential investors.
-
AUD $2m
-
AUD $200,000
-
Employ management team, optimize current candidates, implement patent strategy, complete animal testing for efficacy and toxicity, apply for grant funding.
-
Ordinary shares in Psaio Therapeutics Pty Ltd.
-
Discounted to AUD$15m for this offer – vs AUD$22m valuation in data room.
-
Family members and friends of co-founder shareholders
will also participate in this Seed Capital Raise.
Who We Are
We are a Melbourne-based business that spun out of the world-class antibody discovery company, Myrio Therapeutics. Our experienced team of managers is implementing Psaio Tx's pre-clinical R&D program and will provide periodic updates on LinkedIn and other media outlets.